MedPage Today on MSN4d
Varipulse Returns; HCM Genes Reconsidered; Early Blood Test for Preeclampsia?To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...
Johnson & Johnson MedTech announced that it intends to resume the rollout of its Varipulse platform in the U.S. after a ...
The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...
GlobalData on MSN5d
Johnson & Johnson to resume market release of Varipulse catheter in USJohnson & Johnson is set to resume the limited market release of the Varipulse Catheter, a treatment option for atrial ...
J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...
J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S.
Johnson & Johnson (NYSE: JNJ) announced on Friday that it is set to recommence the limited market release of its VARIPULSE™ devices in the United States. The de ...
This summary covers recent health news, including Wyoming's first human H5N1 bird flu case, WHO's call for cancer warning ...
Johnson & Johnson is relaunching sales of a promising heart-rhythm device after a safety scare, but with a new warning for doctors that analysts say could hamper its market potential ...
Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback